. Enrolment and treatment group allocation in a pilot field trial of Clostridium botulinum type C vaccination for EGS prevention.
Equine grass sickness (EGS) is a polyneuropathy with a case mortality rate of approximately 85%. While epidemiological studies have identified numerous risk factors, there is currently no preventive healthcare measure available for EGS prevention. Previous research suggests that EGS may represent a toxico-infectious form of botulism involving Clostridium botulinum type C. Other equine clostridial diseases are successfully prevented by vaccination, implying that it should be possible to prevent EGS by vaccination. As EGS cannot be induced experimentally, a field trial represents the only method of evaluating the effect of vaccination. This pilot study aimed to inform sample size and trial methodology for a proposed full-scale triple-blinded randomised placebo-controlled field trial of a C. botulinum type C toxoid vaccine in the prevention of EGS. Healthy client-owned horses/ ponies residing on premises previously affected by a high incidence and frequency of EGS were included. Horses/ponies were randomly allocated, at premises-level, stratified by age, to vaccine or placebo treatment groups at a 1:1 ratio. Baseline and follow-up premises and horse data were obtained via telephone questionnaires. Participating veterinary surgeons administered the primary course of vaccine/placebo on days 0, 21, 42, followed by a booster injection on day 224. Following appropriate training, owners completed post-treatment daily observations for seven days following each treatment. Five participating practices recruited 10 EGS-affected premises in Scotland, with a median baseline incidence of 2.2 EGS cases per 100 horse-years-at-risk. 109 horses/ponies were enrolled: 13 were withdrawn prior to randomisation, and 1 was excluded following randomisation ( Figure 1 ). Median age at enrolment was 6 years. Age (p¼0.34), gender (p¼0.15) and breed (p¼0.94) distributions did not differ between treatment groups. 95 horses/ponies completed the primary treatment course, and 87 horses/ponies received booster injections, representing a retention rate of 90.5%. No significant adverse events were reported and incidence of owner-reported injection site abnormalities was 0.05 per horseweek-at-risk, none of which required treatment. One histologically-confirmed EGS case occurred during the study, representing an incidence of 1.25 cases per 100 horse-years-at-risk. There was no difference in the risk of EGS between treatment groups (p¼0.62). Serological analyses demonstrated a significant increase in C. botulinum type C antibody titres following the primary treatment course in vaccinated horses/ponies compared to the placebo group (p<0.001), indicating seroconversion following primary vaccination. This study provided evidence of vaccine safety under conditions of field use, serological evidence of immune response to vaccination and informed modifications to trial methodology for a subsequent nationwide field trial. This study was funded by Neogen Corporation and the Animal Health Trust. A role for bacteriophage therapy was envisaged early last century; however, due to discovery of the antimicrobials, it fell out of research interest. Currently, bacteriophages are resurfacing as an alternative to antimicrobials in order to overcome the increasing incidence of antimicrobial resistance. Here, we report isolation of bacteriophages against Escherichia coli, Shigella spp., Aeromonas hydrophila and Citrobacter sedlakii isolates of equine origin. Phages were isolated from equine farm soil and sewage samples. For enrichment, sample aliquot was incubated overnight with host bacteria at 37 C with vigorous shaking. The crude lysate obtained was centrifuged and filtered and the presence of any phage in the suspension was detected by agar overlay technique. Appropriate dilutions of enriched samples were plated to obtain individual plaques and the most dominant plaque was transferred into SM buffer, serially diluted and plated for plaque re-isolation three times to ensure purity, followed by large scale preparation of phage stocks. Any host nucleic acids was degraded using pancreatic DNaseI and RNase and bacteriophage particles were precipitated using PEG8000. Phage titre was determined by plaque assay and phage concentrates were accessioned in the Veterinary Type Culture Collection (VTCC) repository. The phage concentrates were visualized by transmission electron microscopy (TEM). The temperature stability of bacteriophages was checked after incubating phage concentrates over the range of 4 C -80 C temperature for one hour. A clear single plaque was obtained on nutrient agar against Shigella spp. and after purification and concentration, its analysis by electron microscopy revealed presence of multiple phages belonging to families Myoviridae, Siphoviridae and Podoviridae. However in case of Citrobacter sedlakii, a Siphoviridae phage (VTCCBPA61) with dimensions: 60 nm x 650 nm was observed. Against a pathogenic A. hydrophila isolate of equine origin (expressing aerolysin gene), a Myoviridae phage (VTCCBPA6) was isolated with dimensions: 62 nm x 138 nm. Against E. coli of equine origin, a Myoviridae phage (VTCCBPA9) of dimensions: 86 nm x 100 nm was obtained. Bacteriophage VTCCPBA61 against C. sedlakii was found to completely lose its biological activity at 65 C in vitro however the group of phages against Shigella spp. were found to be stable upto temperature as high as 80 C. Thus we demonstrated the basic biological characteristics of phages, and some novel ones (such as against A. hyrophila and C. sedlakii) bacterial isolates of equine origin which have never been reported till now. These lytic phages could find potential in phage therapy, as biocides, in biosensors and in phage ligand technology and are being explored by us further to depict their therapeutic value in small animal model. As more studies are reporting safety, tolerance and efficacy of phage therapy in humans and animals, their use in phage therapy has a promising future as an emerging alternative to chemical agents. Despite intensive research for more than a hundred years, the cause of Equine Grass Sickness (EGS), has not been found yet. However, it is believed that neurotoxins produced by the bacterium Clostridium (C) botulinum Type C (BoNT) are responsible for the disease. Horse challenge experiments conducted at Central Veterinary Research Laboratory (CVRL), Dubai with C. botulinum Type C toxins as well as with the pathogen itself failed to produce clinical signs of EGS but resulted in the induction of neuromuscular classical botulism. Therefore, we believe that C. botulinum Type C is not the sole agent for EGS and started detailed investigations of the anaerobic flora in the ileal and caecal contents of 2 EGS affected horses and in a soil sample collected from an EGS affected paddock. Samples were processed by special culture and enrichment techniques and the isolated anaerobes were tested for toxin production for four days and their lethality in a mouse bioassay. In total twenty different anaerobes were isolated from the 3 samples. Few anaerobes were isolated in common from ileum, caecum and soil samples, except for C. perfringens with a and b2 gene. Also except for C. perfringens only soil isolates were positive in the mouse bioassay. Strains identified as C. perfringens (a toxin producer, a toxin and b2gene possessing), C. subterminale, and C. septicum were lethal for mice. C. perfringens strains carrying b-2 gene along with the ability to produce a toxin, killed mice within 24 hours and the mice showed typical wasp-waist appearance as seen with botulinum toxin. The toxigenic strains were found to yield toxin on different days of incubation.
